Information released by the State Food and Drug Administration on March 28 shows that in the first quarter of this year, the external licensing transaction volume of my country’s innovative drugs exceeded US$60 billion, nearly half of the total in 2025. As of March 27, 10 innovative drugs have been approved for marketing in my country this year, of which 2 are imported and 8 are domestically produced. Innovative drugs have achieved a historic breakthrough. (Reporter Dai Xiaohe)
